Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. develops clinical-stage protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Company news centers on the rinvatercept (KER-065) program for neuromuscular diseases including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, as well as elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis.
Recurring updates include clinical data presentations, research collaborations, business highlights, financial results, and licensing economics tied to Takeda. Keros also reports governance changes, corporate presentations, portfolio prioritization, and capital actions such as its completed common-stock tender offer and capital return program.
Keros Therapeutics, Inc. (Nasdaq: KROS) has announced the presentation of results from a preclinical study of KER-012 at the upcoming American Heart Association 2021 Scientific Sessions, scheduled from November 13-15, 2021. KER-012 is designed to inhibit certain ligands that suppress bone growth and is being evaluated for treating conditions like osteogenesis imperfecta, osteoporosis, and pulmonary arterial hypertension (PAH). The abstract indicates the potential of KER-012 to attenuate cardiac pathology in models of right ventricle overload.
Keros Therapeutics, Inc. (KROS) reported a net loss of $20.3 million for Q3 2021, up from $12.0 million in Q3 2020, primarily due to heightened research and development efforts. R&D expenses soared to $14.8 million, reflecting aggressive pipeline advancement. The company is progressing with a Phase 2 trial of KER-050 for myelodysplastic syndromes and has initiated a Phase 1 trial for KER-012. Keros has $221.3 million in cash, expected to support operations through Q4 2023. A clinical data update will be provided at the 63rd ASH Annual Meeting in December.
Keros Therapeutics (Nasdaq: KROS) has announced four abstracts for presentation at the 63rd American Society of Hematology Annual Meeting from December 11-14, 2021. Key highlights include preliminary results from the Phase 2 trial of KER-050 for treating anemia in myelodysplastic syndromes (MDS). The abstracts feature clinical presentations on KER-050's efficacy, along with preclinical data supporting its therapeutic potential for cytopenias. Keros aims to address significant unmet medical needs in hematological disorders with its innovative solutions.
Keros Therapeutics, Inc. (Nasdaq: KROS), presented preclinical results of KER-012 at the ASBMR 2021 Annual Meeting, showcasing its efficacy in preventing bone loss in a rodent pulmonary arterial hypertension (PAH) model. RKER-012 demonstrated significant improvements in bone metrics compared to untreated controls, suggesting its potential for treating secondary osteoporosis related to PAH. KER-012 is designed to promote bone growth by inhibiting transforming growth factor-Beta ligands. The company emphasizes KER-012's therapeutic promise for bone loss disorders.
Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that CEO Jasbir S. Seehra, Ph.D., will participate in two healthcare conferences. The events include the Morgan Stanley 19th Annual Global Healthcare Conference on September 10 at 11:00 AM ET as a fireside chat, and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 starting at 7:00 AM ET as a corporate presentation. Both presentations will be accessible online and archived on Keros' investor website for 90 days.
Keros Therapeutics, Inc. (KROS) reported significant progress and financial results for Q2 2021, highlighting advancements in their clinical pipeline. The company announced preliminary results from its Phase 2 trial of KER-050, aimed at treating myelodysplastic syndromes. Financially, Keros posted a net loss of $15.6 million for the quarter, up from $10.8 million in Q2 2020, primarily due to increased R&D and administrative expenses. As of June 30, 2021, Keros held $237.1 million in cash, sufficient to fund operations through Q4 2023.
Keros Therapeutics has appointed Simon Cooper as Chief Medical Officer, effective August 2, 2021. Cooper brings extensive experience from companies like Kadmon Holdings and AbbVie. His role will be crucial as Keros advances its clinical pipeline, particularly the promising KER-050 program. He succeeds Claudia Ordonez, who will continue consulting until September 15, 2021. The company focuses on developing novel therapeutics for hematological and musculoskeletal disorders, targeting significant unmet medical needs.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced preliminary results from its Phase 2 trial of KER-050 for treating anemia and thrombocytopenia in patients with myelodysplastic syndromes. As of May 14, 2021, twelve patients were treated, with five achieving significant hematological endpoints. The drug was well tolerated, with no serious drug-related adverse events reported. Based on the results, Keros will extend the trial duration to up to two years and initiate further trial phases. A conference call is scheduled for June 23, 2021, to discuss these findings.
Keros Therapeutics (KROS) presented significant preclinical data at the EHA2021 Virtual Congress, highlighting the efficacy of ALK2 inhibition and the novel therapy KER-050. Studies showed that ALK2 inhibition reduced hepcidin levels and improved iron homeostasis in models of anemia and iron overload. KER-050 exhibited rapid and sustainable effects on erythropoiesis and increased erythropoietin levels, supporting its potential as a treatment for myelodysplastic syndromes and myelofibrosis. Results indicate promising therapeutic avenues for conditions related to elevated hepcidin.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced that its President and CEO, Jasbir S. Seehra, Ph.D., will present at the Jefferies Virtual Healthcare Conference on June 1 at 2:00 PM EST. The presentation will be available via a live webcast and will also be archived on Keros' Investors section for 90 days. Keros focuses on developing innovative treatments for hematological and musculoskeletal disorders, with key product candidates including KER-050 for cytopenias, KER-047 for anemia from iron imbalance, and KER-012 for bone loss and pulmonary arterial hypertension.